title: High-dose methylprednisolone pulse therapy upregulated FcγRIIb expression on B cells in primary Sjögren's syndrome patients with thrombocytopenia.
abstract: Abnormalities in B cell are characteristic feature of primary Sjögren's syndrome (pSS). As FcγRIIb is a key regulator of B cells, the objective of this study is to investigate the role of the inhibitory receptor FcγRIIb in B cells from pSS patients, and whether glucocorticoid can affect B cell subpopulations or FcγRIIb expression. Thirty pSS patients and 15 healthy controls were enrolled in this study. The results showed that the percentage of memory CD19(+)CD27(+) B cells was significantly lower in pSS patients compared to in healthy controls. FcγRIIb expression on memory CD19(+)CD27(+) B cells from active pSS patients was significantly reduced compared with those from inactive or healthy controls. The level of FcγRIIb on memory CD19(+)CD27(+) B cells from active pSS patients was negatively correlated with anti-SSA antibody titers and Sjögren's syndrome disease activity index. After a high-dose methylprednisolone pulse therapy for 3 days, FcγRIIb expression on memory B cells was upregulated, with the raised level of platelets. In vitro, dexamethasone could elevate FcγRIIb expression on B cells of pSS patients in a dose-dependent manner. Taken together, our data suggest that the upregulation of FcγRIIb may be expected to be a new therapeutic strategy in pSS patients.
authors.affiliation: Department of Immunology and Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Haifeng
authors.initials: H
authors.lastname: Chen
authors.forename: Shiliang
authors.initials: S
authors.lastname: Zhou
authors.forename: Dinglei
authors.initials: D
authors.lastname: Su
authors.forename: Liwei
authors.initials: L
authors.lastname: Lu
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.forename: Lingyun
authors.initials: L
authors.lastname: Sun
mesh_terms: D000328:Adult; D018941:Antigens, CD19 / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D016022:Case-Control Studies; D003907:Dexamethasone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007156:Immunologic Memory / Q000276:immunology; D016130:Immunophenotyping; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D010976:Platelet Count; D017452:Receptors, IgG / Q000378:metabolism*; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000150:complications / Q000188:drug therapy*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D018941:Antigens, CD19; C080571:Fc gamma receptor IIB; D017452:Receptors, IgG; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D003907:Dexamethasone; D008775:Methylprednisolone
references.citation: Ann Rheum Dis. 2008 Feb;67(2):154-61
references.pmid: 17557887
references.citation: Rheumatol Int. 2012 May;32(5):1353-5
references.pmid: 20237930
references.citation: J Exp Med. 2002 Apr 15;195(8):1079-85
references.pmid: 11956299
references.citation: Nat Rev Immunol. 2008 Jan;8(1):34-47
references.pmid: 18064051
references.citation: J Thromb Haemost. 2006 Aug;4(8):1664-72
references.pmid: 16879206
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19571-8
references.pmid: 19036920
references.citation: J Immunol. 2001 Oct 1;167(7):3610-8
references.pmid: 11564773
references.citation: Ann Rheum Dis. 2009 Sep;68(9):1447-52
references.pmid: 18782791
references.citation: Immunity. 2003 Apr;18(4):573-81
references.pmid: 12705859
references.citation: Neth J Med. 2006 Apr;64(4):103-8
references.pmid: 16609156
references.citation: Nat Rev Rheumatol. 2010 Sep;6(9):529-37
references.pmid: 20683439
references.citation: Nat Rev Immunol. 2010 May;10(5):328-43
references.pmid: 20414206
references.citation: Clin Exp Rheumatol. 2011 Jan-Feb;29(1):6-12
references.pmid: 21345287
references.citation: J Autoimmun. 2010 Nov;35(3):241-7
references.pmid: 20655174
references.citation: Immunology. 2003 Mar;108(3):263-73
references.pmid: 12603592
references.citation: Nat Immunol. 2007 Apr;8(4):419-29
references.pmid: 17322888
references.citation: J Autoimmun. 2009 May-Jun;32(3-4):149-57
references.pmid: 19327966
references.citation: J Rheumatol. 2002 Jan;29(1):75-83
references.pmid: 11824975
references.citation: J Immunol. 2007 Mar 1;178(5):3272-80
references.pmid: 17312177
references.citation: Eur J Immunol. 1995 Jul;25(7):1865-71
references.pmid: 7621863
references.citation: Arthritis Res Ther. 2010;12(2):R68
references.pmid: 20398308
references.citation: Arthritis Rheum. 2002 Aug;46(8):2160-71
references.pmid: 12209521
references.citation: J Clin Immunol. 2010 May;30 Suppl 1:S9-14
references.pmid: 20480216
references.citation: Blood. 2011 Feb 10;117(6):2061-9
references.pmid: 21131591
references.citation: Arthritis Rheum. 2007 Mar 15;57(2):310-7
references.pmid: 17330280
references.citation: Arthritis Rheum. 2008 Feb;58(2):384-8
references.pmid: 18240208
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4788-92
references.pmid: 19261857
references.citation: Ann Rheum Dis. 2002 Jun;61(6):554-8
references.pmid: 12006334
references.citation: J Immunol. 2008 Apr 15;180(8):5670-9
references.pmid: 18390752
references.citation: J Autoimmun. 2012 Sep;39(3):161-7
references.pmid: 22749831
references.citation: South Med J. 2001 Dec;94(12):1219-22
references.pmid: 11811865